{ }
001122334455554433221100
001122334455554433221100

former turing ceo reflects on crisis after shkreli's arrest

Ron Tilles, who stepped in as interim CEO of Turing Pharmaceuticals after Martin Shkreli's arrest, faced immense challenges managing the fallout from the company's notorious 5,000% price hike of Daraprim. Despite his limited knowledge of the pharmaceutical industry, Tilles worked to stabilize the company amid bankruptcy threats and public outrage, ultimately leading to its rebranding as Vyera Pharmaceuticals. Now a board member at Pyros Pharmaceuticals, Tilles emphasizes the importance of fair pricing in the industry, reflecting on the lessons learned from Turing's tumultuous past.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Machinary - Dashboard

Client connection lost

Please check your connection. We try to reconnect...

Server connection lost

If our server is updating to a new version, please wait a moment before the service is available again.

Connection refused

All connection attempts have been rejected. This is most likely due to network problems or server problems.